Seattle Genetics Bulks Up Its Pipeline

Nothing's nicer to see than a development-stage drugmaker that advances its compounds through the clinic in a timely and smart manner. Seattle Genetics (Nasdaq: SGEN  ) has recently announced its initiation of new phase 1 studies for its anticancer drugs dubbed SGN-33 and SGN-35.

SGN-33 is in phase 1 and 2 testing as a treatment for acute myeloid leukemia and myelodysplastic syndromes (formerly known as "preleukemia"). SGN-35 is in phase 1 testing as a treatment for Hodgkin's lymphoma. Both are biopharmaceuticals. New data from SGN-33 is expected in the second half of 2008, with study results from SGN-35 coming by July.

Last year's inking of a very healthy collaboration deal with Genentech (NYSE: DNA  ) marked the start of a rapid evolution in the prospects for Seattle Genetics' lead drug, SGN-40. This compound is now set to ramp up to a total of six early and mid-stage studies in non-Hodgkin's lymphoma and multiple myeloma in combination with some of biotechs' top compounds, like Genentech's Rituxan and Millennium Pharmaceuticals' (Nasdaq: MLNM  ) Velcade.

Biopharmaceutical drugs are being valued at a premium to their small molecule counterparts, thanks to the indefinite de facto freedom from generic competition that now exists for biologics. Seattle Genetics stands out as one of the biggest development-stage pharmas with multiple unpartnered biopharmaceuticals in its pipeline that treat indications where biologics have proven themselves in the past.

All biotech investors should continue to watch closely the progress and early stage results that will be coming out later this year for Seattle Genetics' compounds.

More biotech Foolishness:

Read/Post Comments (0) | Recommend This Article (5)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 612045, ~/Articles/ArticleHandler.aspx, 10/27/2016 5:33:05 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 8 hours ago Sponsored by:
DOW 18,199.33 30.06 0.17%
S&P 500 2,139.43 -3.73 -0.17%
NASD 5,250.27 -33.13 -0.63%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/26/2016 4:00 PM
SGEN $50.33 Down -0.05 -0.10%
Seattle Genetics CAPS Rating: ****
DNA $94.97 Down +0.00 +0.00%
Genentech CAPS Rating: ****
MLNM.DL $24.97 Down +0.00 +0.00%
Millennium Pharmac… CAPS Rating: No stars